0.2531 0.011 (4.59%) | 12-23 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 10.35 ![]() |
1-year : | 14.65 |
Resists | First : | 8.86 ![]() |
Second : | 12.55 |
Pivot price | 3.93 ![]() |
|||
Supports | First : | 2.9 ![]() |
Second : | 2.41 ![]() |
MAs | MA(5) : | 5.09 ![]() |
MA(20) : | 3.79 ![]() |
MA(100) : | 4.19 ![]() |
MA(250) : | 8.01 ![]() |
|
MACD | MACD : | 0.4 ![]() |
Signal : | 0.2 ![]() |
%K %D | K(14,3) : | 24.1 ![]() |
D(3) : | 22.4 ![]() |
RSI | RSI(14): 63.9 ![]() |
|||
52-week | High : | 16.07 | Low : | 0.24 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BNOX ] has closed below upper band by 11.7%. Bollinger Bands are 20.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 5.75 - 5.78 | 5.78 - 5.8 |
Low: | 5.05 - 5.08 | 5.08 - 5.1 |
Close: | 5.25 - 5.3 | 5.3 - 5.34 |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.
Mon, 16 Dec 2024
Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation - GlobeNewswire
Mon, 16 Dec 2024
Bionomics Secures Major Court Approval for Strategic US Market Shift, Sets December Trading Timeline - StockTitan
Thu, 12 Dec 2024
Bionomics Secures 96% Shareholder Approval for US Re-domiciliation, Plans Nasdaq Listing as Neuphoria - StockTitan
Mon, 02 Dec 2024
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States - Yahoo Finance
Fri, 08 Nov 2024
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement - GlobeNewswire
Tue, 05 Nov 2024
Why Bionomics (BNOX) Stock Is Up 100% Today - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 2 (M) |
Held by Insiders | 2.61e+009 (%) |
Held by Institutions | 33.9 (%) |
Shares Short | 73 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.735e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 8 % |
Return on Assets (ttm) | 909.6 % |
Return on Equity (ttm) | -39.6 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | -5.40217e+006 |
Sales Per Share | 3.27174e+006 |
EBITDA (p.s.) | -1.08315e+007 |
Qtrly Earnings Growth | -14.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0.29 |
Dividend | 0 |
Forward Dividend | 190270 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |